Sarah A Best1, Jonas B Hess1, Fernando Souza-Fonseca-Guimaraes2, Joseph Cursons3, Ariena Kersbergen4, Xueyi Dong5, Jai Rautela6, Stephanie R Hyslop1, Matthew E Ritchie7, Melissa J Davis8, Tracy L Leong9, Louis Irving10, Daniel Steinfort10, Nicholas D Huntington11, Kate D Sutherland12. 1. ACRF Cancer Biology and Stem Cells Division, The Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia; Department of Medical Biology, The University of Melbourne, Parkville, Victoria, Australia. 2. University of Queensland Diamantina Institute, University of Queensland, Brisbane, Queensland, Australia; Translational Research Institute, Brisbane, Queensland, Australia; Molecular Immunology Division, The Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia. 3. Department of Medical Biology, The University of Melbourne, Parkville, Victoria, Australia; Bioinformatics Division, The Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia; Department of Biochemistry and Molecular Biology, Biomedicine Discovery Institute, Monash University, Clayton, Victoria, Australia. 4. ACRF Cancer Biology and Stem Cells Division, The Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia. 5. Department of Medical Biology, The University of Melbourne, Parkville, Victoria, Australia; Epigenetics and Development Division, The Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia. 6. Department of Biochemistry and Molecular Biology, Biomedicine Discovery Institute, Monash University, Clayton, Victoria, Australia. 7. Epigenetics and Development Division, The Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia; School of Mathematics and Statistics, The University of Melbourne, Parkville, Australia. 8. Department of Medical Biology, The University of Melbourne, Parkville, Victoria, Australia; Bioinformatics Division, The Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia. 9. Department of Medicine, University of Melbourne, Parkville, Victoria, Australia; Department of Respiratory and Sleep Medicine, Austin Hospital, Heidelberg, Victoria, Australia; Personalised Oncology Division, The Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia. 10. Department of Medicine, University of Melbourne, Parkville, Victoria, Australia; Department of Respiratory Medicine, Royal Melbourne Hospital, Parkville, Victoria, Australia. 11. Department of Medical Biology, The University of Melbourne, Parkville, Victoria, Australia; Molecular Immunology Division, The Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia; Department of Biochemistry and Molecular Biology, Biomedicine Discovery Institute, Monash University, Clayton, Victoria, Australia. 12. ACRF Cancer Biology and Stem Cells Division, The Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia; Department of Medical Biology, The University of Melbourne, Parkville, Victoria, Australia. Electronic address: sutherland.k@wehi.edu.au.
Abstract
INTRODUCTION: SCLC is the most aggressive subtype of lung cancer, and though most patients initially respond to platinum-based chemotherapy, resistance develops rapidly. Immunotherapy holds promise in the treatment of lung cancer; however, patients with SCLC exhibit poor overall responses highlighting the necessity for alternative approaches. Natural killer (NK) cells are an alternative to T cell-based immunotherapies that do not require sensitization to antigens presented on the surface of tumor cells. METHODS: We investigated the immunophenotype of human SCLC tumors by both flow cytometry on fresh samples and bioinformatic analysis. Cell lines generated from murine SCLC were transplanted into mice lacking key cytotoxic immune cells. Subcutaneous tumor growth, metastatic dissemination, and activation of CD8+ T and NK cells were evaluated by histology and flow cytometry. RESULTS: Transcriptomic analysis of human SCLC tumors revealed heterogeneous immune checkpoint and cytotoxic signature profiles. Using sophisticated, genetically engineered mouse models, we reported that the absence of NK cells, but not CD8+ T cells, substantially enhanced metastatic dissemination of SCLC tumor cells in vivo. Moreover, hyperactivation of NK cell activity through augmentation of interleukin-15 or transforming growth factor-β signaling pathways ameliorated SCLC metastases, an effect that was enhanced when combined with antiprogrammed cell death-1 therapy. CONCLUSIONS: These proof-of-principle findings provide a rationale for exploiting the antitumor functions of NK cells in the treatment of patients with SCLC. Moreover, the distinct immune profiles of SCLC subtypes reveal an unappreciated level of heterogeneity that warrants further investigation in the stratification of patients for immunotherapy.
INTRODUCTION:SCLC is the most aggressive subtype of lung cancer, and though most patients initially respond to platinum-based chemotherapy, resistance develops rapidly. Immunotherapy holds promise in the treatment of lung cancer; however, patients with SCLC exhibit poor overall responses highlighting the necessity for alternative approaches. Natural killer (NK) cells are an alternative to T cell-based immunotherapies that do not require sensitization to antigens presented on the surface of tumor cells. METHODS: We investigated the immunophenotype of humanSCLC tumors by both flow cytometry on fresh samples and bioinformatic analysis. Cell lines generated from murineSCLC were transplanted into mice lacking key cytotoxic immune cells. Subcutaneous tumor growth, metastatic dissemination, and activation of CD8+ T and NK cells were evaluated by histology and flow cytometry. RESULTS: Transcriptomic analysis of humanSCLC tumors revealed heterogeneous immune checkpoint and cytotoxic signature profiles. Using sophisticated, genetically engineered mouse models, we reported that the absence of NK cells, but not CD8+ T cells, substantially enhanced metastatic dissemination of SCLC tumor cells in vivo. Moreover, hyperactivation of NK cell activity through augmentation of interleukin-15 or transforming growth factor-β signaling pathways ameliorated SCLC metastases, an effect that was enhanced when combined with antiprogrammed cell death-1 therapy. CONCLUSIONS: These proof-of-principle findings provide a rationale for exploiting the antitumor functions of NK cells in the treatment of patients with SCLC. Moreover, the distinct immune profiles of SCLC subtypes reveal an unappreciated level of heterogeneity that warrants further investigation in the stratification of patients for immunotherapy.
Authors: Joseph M Chan; Álvaro Quintanal-Villalonga; Vianne Ran Gao; Yubin Xie; Viola Allaj; Ojasvi Chaudhary; Ignas Masilionis; Jacklynn Egger; Andrew Chow; Thomas Walle; Marissa Mattar; Dig V K Yarlagadda; James L Wang; Fathema Uddin; Michael Offin; Metamia Ciampricotti; Besnik Qeriqi; Amber Bahr; Elisa de Stanchina; Umesh K Bhanot; W Victoria Lai; Matthew J Bott; David R Jones; Arvin Ruiz; Marina K Baine; Yanyun Li; Natasha Rekhtman; John T Poirier; Tal Nawy; Triparna Sen; Linas Mazutis; Travis J Hollmann; Dana Pe'er; Charles M Rudin Journal: Cancer Cell Date: 2021-10-14 Impact factor: 31.743
Authors: Evelyn M Nguyen; Hirokazu Taniguchi; Joseph M Chan; Yingqian A Zhan; Xiaoping Chen; Juan Qiu; Elisa de Stanchina; Viola Allaj; Nisargbhai S Shah; Fathema Uddin; Parvathy Manoj; Michael Liu; Sheng F Cai; Ross Levine; Álvaro Quintanal-Villalonga; Triparna Sen; Andrew Chow; Charles M Rudin Journal: J Thorac Oncol Date: 2022-06-09 Impact factor: 20.121
Authors: Marie Menard; Benjamin A H Smith; Miles H Linde; Johanna Theruvath; Garry L Coles; Guillermo Nicolas Dalton; Wei Wu; Louise Kiru; Alberto Delaidelli; Elena Sotillo; John L Silberstein; Anna C Geraghty; Allison Banuelos; Molly Thomas Radosevich; Shaurya Dhingra; Sabine Heitzeneder; Aidan Tousley; John Lattin; Peng Xu; Jing Huang; Nicole Nasholm; Andy He; Tracy C Kuo; Emma R B Sangalang; Jaume Pons; Amira Barkal; Rachel E Brewer; Kristopher D Marjon; Jose G Vilches-Moure; Payton L Marshall; Ricardo Fernandes; Michelle Monje; Jennifer R Cochran; Poul H Sorensen; Heike E Daldrup-Link; Irving L Weissman; Julien Sage; Ravindra Majeti; Carolyn R Bertozzi; William A Weiss; Crystal L Mackall; Robbie G Majzner Journal: Nat Med Date: 2022-01-13 Impact factor: 87.241
Authors: Hui-Zi Chen; Russell Bonneville; Anoosha Paruchuri; Julie W Reeser; Michele R Wing; Eric Samorodnitsky; Melanie A Krook; Amy M Smith; Thuy Dao; Jharna Miya; Walter Wang; Lianbo Yu; Aharon G Freud; Patricia Allenby; Sharon Cole; Gregory Otterson; Peter Shields; David P Carbone; Sameek Roychowdhury Journal: JTO Clin Res Rep Date: 2021-03-11
Authors: Laura Ducimetière; Giulia Lucchiari; Gioana Litscher; Marc Nater; Laura Heeb; Nicolás Gonzalo Nuñez; Laura Wyss; Dominik Burri; Marijne Vermeer; Julia Gschwend; Andreas E Moor; Burkhard Becher; Maries van den Broek; Sonia Tugues Journal: Proc Natl Acad Sci U S A Date: 2021-07-06 Impact factor: 11.205